AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

TENOFOVIR ALAFENAMIDE FUMARATE

7 registrations across 3 African markets— 7 active

Markets with TENOFOVIR ALAFENAMIDE FUMARATE

Recent registrations

Brand / ProductMarketHolderStatusExpires
HepBest
Film-Coated Tablet
🇰🇪KenyaMylan Laboratories LimitedactiveFeb 2031
Vemlidy 25 mg Tablets**
Tablet
🇳🇬NigeriaPhillips Pharmaceuticals (Nigeria) LimitedactiveSept 2029
TAFIGADO
TABLET; ORAL
🇿🇼ZimbabweMYLAN LABORATORIES LIMITEDactiveJan 2029
TENOFOVIR ALAFENAMIDE
TABLET, COATED; ORAL
🇿🇼ZimbabweLAURUS LABS LIMITEDactiveOct 2028
TENOFOVIR ALAFENAMIDE
TABLET, COATED; ORAL
🇿🇼ZimbabweHETERO LABS LTDactiveJul 2028
Hepbest 25 mg
Tablet
🇳🇬NigeriaHealthline LimitedactiveSept 2026
Getinomide Tablets 25 mg
Tablet
🇳🇬NigeriaGetz Pharma Nigeria LimitedactiveNov 2025

TENOFOVIR ALAFENAMIDE FUMARATE in Africa — Regulatory Overview

TENOFOVIR ALAFENAMIDE FUMARATE is registered across 3 African markets with 7 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Nigeria, Zimbabwe, Kenya. AfricaRegulatory refreshes this data daily from official government sources.

Of the 7 registrations, 7 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.